268 related articles for article (PubMed ID: 25972361)
1. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.
Wilson AJ; Fadare O; Beeghly-Fadiel A; Son DS; Liu Q; Zhao S; Saskowski J; Uddin MJ; Daniel C; Crews B; Lehmann BD; Pietenpol JA; Crispens MA; Marnett LJ; Khabele D
Oncotarget; 2015 Aug; 6(25):21353-68. PubMed ID: 25972361
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
4. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
5. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
6. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
7. Epithelial/mesenchymal heterogeneity of high-grade serous ovarian carcinoma samples correlates with miRNA let-7 levels and predicts tumor growth and metastasis.
Chirshev E; Hojo N; Bertucci A; Sanderman L; Nguyen A; Wang H; Suzuki T; Brito E; Martinez SR; Castañón C; Mirshahidi S; Vazquez ME; Wat P; Oberg KC; Ioffe YJ; Unternaehrer JJ
Mol Oncol; 2020 Nov; 14(11):2796-2813. PubMed ID: 32652647
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
Haley J; Tomar S; Pulliam N; Xiong S; Perkins SM; Karpf AR; Mitra S; Nephew KP; Mitra AK
Oncotarget; 2016 May; 7(22):32810-20. PubMed ID: 27147568
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Popa I; Bachvarov D
Int J Oncol; 2017 Dec; 51(6):1887-1897. PubMed ID: 29039611
[TBL] [Abstract][Full Text] [Related]
11. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
12. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.
Beeghly-Fadiel A; Wilson AJ; Keene S; El Ramahi M; Xu S; Marnett LJ; Fadare O; Crispens MA; Khabele D
J Ovarian Res; 2018 Feb; 11(1):17. PubMed ID: 29482584
[TBL] [Abstract][Full Text] [Related]
13. c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer.
Jin Y; Huang M; Wang Y; Yi C; Deng Y; Chen Y; Jiang L; Wang J; Shen Q; Liu R; QinghuaXi
Exp Mol Pathol; 2016 Aug; 101(1):50-7. PubMed ID: 27289010
[TBL] [Abstract][Full Text] [Related]
14. Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.
Li H; Xiao N; Li Z; Wang Q
Tohoku J Exp Med; 2017 Feb; 241(2):165-173. PubMed ID: 28202851
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer.
Ibrahim FF; Jamal R; Syafruddin SE; Ab Mutalib NS; Saidin S; MdZin RR; Hossain Mollah MM; Mokhtar NM
J Ovarian Res; 2015 Aug; 8():56. PubMed ID: 26260454
[TBL] [Abstract][Full Text] [Related]
16. Aromatase expression in ovarian epithelial cancers.
Cunat S; Rabenoelina F; Daurès JP; Katsaros D; Sasano H; Miller WR; Maudelonde T; Pujol P
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):15-24. PubMed ID: 15748828
[TBL] [Abstract][Full Text] [Related]
17. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier.
Martins FC; Santiago Id; Trinh A; Xian J; Guo A; Sayal K; Jimenez-Linan M; Deen S; Driver K; Mack M; Aslop J; Pharoah PD; Markowetz F; Brenton JD
Genome Biol; 2014 Dec; 15(12):526. PubMed ID: 25608477
[TBL] [Abstract][Full Text] [Related]
18. [Expression and significance of matriptase in ovarian cancer cells with diverse metastatic potential].
Jiang ZQ; Chen XF; Sun PM; Mao XD; Lin F; Song YY
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):370-4. PubMed ID: 24016481
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
[TBL] [Abstract][Full Text] [Related]
20. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
Luo X; Cao J; Zhang C; Huang H; Liu J
Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
